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Abstract
The aim of this investigation was to assess the bioavailability and pharmacokinetics of oxytocin in six male 
subjects after a sublingual dose of 400 int. units (684 /xg) and after an intravenous dose of 1 int. unit 
(1*71 /¿g).
After intravenous administration, the pharmacokinetic profile could be described with a two-compart­
ment model. The distribution half-life was 0-049 ±  0*016 h, the elimination half-life was 0-33 db 0*23 h, the 
total body clearance was 67*1 ±  13-4Lh‘ 1 and the volume of distribution was 33-2 ±  28-1 L. After 
sublingual administration, a poor bioavailability with a 10-fold variation between 0-007 and 0-07% was 
observed. The pharmacokinetic profile could be described with a one-compartment model. The lag time 
was subject-dependent and ranged between 0-12 and 0*30 h (40% CV). The absorption half-life was 
0*45 ±  0’29 h, and the apparent elimination half-life 0-69 ±  0-26h.
This study showed a very poor and interindividual variability in bioavailability. The sublingual route of 
administration with its 'long’ lag time and 'long’ absorption half-life would not seem a reliable route for 
accurate high dosing for immediate prevention of post-partum haemorrhage.
Postpartum haemorrhage (PPH) is still one of the most 
common causes of maternal death (Royston & Armstrong
1989). In such cases death invariably occurs within a few 
hours after childbirth. Prevention and management of this 
condition should take place at all levels of obstetric care as 
emergency referral is often dillicult to arrange, especially in 
circumstances prevailing in many third-wo rid countries. 
Oxytocin belongs to the group of oxytocic drugs enhancing 
uterine motility. Prophylactic use of these drugs in the third 
stage of labour reduces the risk of PPH and the need for 
further oxytocic therapy in the puerperium (van Dongen et 
al 1991). The use of oxytocics in the post-partum period is 
advocated for the prevention and the management of PPH 
(Prendiville et al 1988a, b; Royston & Armstrong 1989; 
WHO 1990).
Drugs in tropical climates must fulfil extra requirements. 
They need to be stable (Walker et al 1988; Hogerzeil et al 
1991, 1992) and the route of administration should be 
simple. Also untrained people should be able to administer 
the drug safely. Compared with other oxytocics, oxytocin is 
the preferred drug in the prevention and management of 
blood loss after childbirth because it is more stable under 
(simulated) tropical conditions and gives less side-effects 
(McDonald et al 1993; Hogerzeil et al 1994). In general, 
oxytocin is administered intramuscularly. Besides oxytocin 
ampoules, preparations for intranasal and buccal or sub­
lingual administration exist.
Correspondence: T. B, Vree, Department of Clinical Pharmacy, 
Academic Hospital Nijmegen, Sint Radboud, PO Box 9101, 6500 
MB Nijmegen, The Netherlands.
Pharmacokinetic studies on sublingual oxytocin are 
scarce and show an unfavourable latent period of the 
oxytocic effect after drug administration of 26-53 min 
(Obolensky & Kupferschmied 1969; Tobias 1975; Da wood 
et al 1980). Sublingual demoxytocin tablets are not widely 
used as greater control is accorded by intravenous or 
intramuscular administration and because sublingual 
absorption is more unpredictable (Noriega-Guerra et al 
1966). Despite unfavourable absorption data we thought it 
useful to examine whether sublingual oxytocin would be an 
acceptable non-parenteral prophylactic oxytocic. Published 
pharmacokinetic studies used small numbers of patients and 
were not fully convincing on the limitations of sublingual 
oxytocin as an alternative non-parenteral oxytocic for active 
management of the third stage of labour.
To assess the pharmacokinetics of sublingual oxytocin, 
male volunteers were used. Experiments in female volun­
teers introduce possible difficulties because of (higher) 
circadian levels of endogenous oxytocin levels as shown in 
pregnancy (Honnebier 1993). A constant low ( < 3 pgmL-1) 
endogenous level of oxytocin was measured in male volun­
teers. Plasma elevation after sublingual administration of 
200 int. units (one dose) was too low (de Groot et al 
unpublished results); therefore a dose of two tablets 
(400 int. units = 684 ^ g) was chosen. RIA analysis was devel­
oped to enable the pharmacokinetic analysis of oxytocin.
Materials and Methods
Subjects
Six male volunteers were screened for possible contra­
indications (cardiovascular disease and chronic obstructive
Table 1. Demographic data of six male volunteers.
572 AKOSUA R J. A. DE GROOT ET AL
Subject
1 2 3 4 5 6
Age (years) 53 18 34 26 42 26
Weight (kg) 79 71 78 74 85 61
Height (cm) 179 190 182 179 175 178
Blood pressure 120/70 110/70 120/65 120/78 120/80 115/80 
Basal oxytocin concn (pgmL-1)“
Sublingual 1 «70 ±0-40 1*10±0*10 1*30 ± 0-26 1-15 ±0*23 1-26 ±0-21 0*87±0'29
Intravenous 0*90 ± 017 l-33±0*35 1-57 ±0-23 1-43 ±0*25 1-50 ±0*26 1-30 =fc 0-10
an = 3,
lung disease). Body-weight/height, blood pressure, hae­
moglobin level, liver and renal functions were recorded 
(Table 1). All subjects had normal liver and renal func­
tions. During the experiments blood presure was monitored. 
This study was approved by the Committee Experimental 
Research Involving Human Subjects (CEOM) of the 
Academic Hospital Nijmegen Sint Radboud, Nijmegen, 
The Netherlands.
Standard. The oxytocin standard (0-6379; Sigma) was 
calibrated against the WHO standard 76/575 (National 
Institute for Biological Standard and Control, South 
Mimms, Hertfordshire, UK).
Labelling. Oxytocin was iodinated with N al25I using the 
lactoperoxidase method with Enzymobead, followed by 
purification using Sep-pack C18 cartridges.
Drugs
Pure oxytocin (0-6379) was obtained from Sigma (St Louis, 
MO, USA). Oxytocin for intravenous administration 
(Syntocinon) was obtained from Sandoz Pharma AG, 
(Basel, Switzerland). Oxytocin for sublingual administra­
tion (Pitocin) was obtained from Parke-Davis GmbH, 
Gôdecke AG, (Berlin, Germany). The pure oxytocin ma­
terial fulfilled the requirements of a content uniformity test 
according to standard quality control criteria. Intravenous 
and sublingual preparations conformed with the NIBSC 
standard.
Dosage
The dosages were administered in a cross-over design. A 
single sublingual dose of oxytocin (400 int. units = 684 /zg) 
was taken after a standard breakfast containing two sand­
wiches, no cheese and unrestricted amounts of coffee or tea. 
Two weeks later 1 int. unit (1*71 pg) oxytocin was injected 
intravenously to the same volunteer after a similar standard 
breakfast.
Sampling
Sublingual administration. Five-millilitre blood samples were 
collected through an intravenous canula (Venflon 1*0 mm 
o.d.) in tubes containing 0-5 mg EDTA at times: -10, —5, 0, 
10, 20, 30, 40, 50, 60, 90, 180, 240, 270, 300min after 
oxytocin administration.
Intravenous administration. Intravenous injection took place 
over lmin in the opposite arm where the Venflon was 
located. In addition to the sampling times as described for 
sublingual administration, two extra samples were taken 3 
and 5 min after the start of the injection.
Drug assay
Oxytocin in plasma was measured by RIA as described by 
Dogterom et al (1977), with some modifications as follows.
Antiserum. Polyclonal rabbit anti-oxytocin was kindly 
donated by Dr T. Higuchi (Kochi, Japan) (Higuchi et al 
1985), and used in a final dilution of 1:600000. Cross­
reactivities for arginine-vasopressin, lysine-vasopressin, 
arginine-vasotocin, deamino-D-arginine-vasopressin were 
< 0*01% and for isotocin 0*9% (on mass bases).
Sample preparation. Oxytocin was extracted from 2*0 mL 
EDTA plasma using Sep-Pak C18 cartridges.
Assay. Oxytocin was measured by non-equilibrium radio­
immunoassay. Rabbit oxytocin antiserum (50 pL) (final 
dilution 1:600 000 and diluted in oxytocin RIA-buffer 
(0*02 m phosphate buffer (pH 7*4) containing 13 mM 
EDTA, 0*02% sodium azide, 0*25% BSA, 0*1% Triton 
X-100 and 250 000 int. units aprotonin (Trasylol) mL"1)) 
was added to 50 pL  sample or standard. The mixture was 
preincubated for three days at 4°CS then, tracer (approx. 
6000 disintegration vohr1 ¡50 pL) was added and incubation 
was continued for another day. Bound and free oxytocin 
were separated by a second antibody by addition of 100 pL  
10% sheep antirabbit IgG and 0*01 % rabbit IgG and 1 *0 mL 
7*5% polyethylene glycol 6000 solution. The standard curve 
for the oxytocin assay was run in triplicate with a range of 
0*25-32 pg per assay tube.
Assay performance. The sensitivity of the assay system was 
0-32 pgmL-1 (extraction of 2mL plasma). There was 50% 
displacement for l ‘25pg, Within-assay and between-assay 
coefficients of variation of the extraction and RIA pro­
cedure were < 8%. Recovery of oxytocin added to plasma 
was about 80%. Oxytocin values of 15 normal male 
volunteers was < 3 p g m L '1.
Pharmacokinetic analysis
Net plasma concentrations were used (total oxytocin in the 
sample minus mean baseline value) (n =  3, at t =  - 1 0 min,
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- 5 min, and Oh of each subject). Curve-fitting was carried 
out (r2 > 0-97) and pharmacokinetic parameters were cal­
culated using the two-compartment model after intravenous 
administration and the one-compartment model with extra- 
vascular administration and lag time of the MW/Pharm 
computer program (Mediware, Groningen, The Nether­
lands) (Proost & Meyer 1992). Cm(W is the maximum 
plasma concentration read from the fitted plasma concen­
tration-time curve, and tmax the time at which Cmax occurs. 
The tè/i values were calculated from ln(2)//3, where ft is 
calculated by log-linear regression analysis of the terminal 
log-linear phase. The t5abs and tj were obtained by line 
feathering and linear regression analysis. A U Cq^ is the 
area under the plasma concentration-time curve and was 
calculated using the linear trapezoidal rule with extrapola­
tion of t =  oo, using Ct/fi  with Ct being the last measured 
concentration. Total body clearance CL =  Dose/AUCo^.
The bioavailability (F) is AUCorarDoseiiV7AUCjiV/Doseoral. 
Vdss is the volume of distribution at steady state 
(Vdss =  Dose x AUMCo- oo/AUCq- oo 2). Mean absorption 
time after sublingual administration (MATS) was defined 
as [MRTS -  tlag] -  [MRTiJ.
Average values are expressed as means ±s.d. The statis­
tical significance was determined by analysis of variance. A 
value of P < 0-05 was considered significant.
Results
Fig. 1 shows the oxytocin plasma concentration-time curves 
after sublingual administration of 400 int. units (684 jug) 
oxytocin and after intravenous administration of lint, 
unit ( 1 *71 fig) in one male volunteer (subject 1). After 
sublingual administration the compound is rapidly 
absorbed after a lag time of 0-28 h. A maximum plasma 
concentration of 7*9pgmL~1 was reached after 0*59 h. The 
apparent half-life of oxytocin was 0-62 h in this volunteer. 
After the intravenous administration the half-life was 0*28 h. 
The relative bioavailability (F) in this subject was calculated 
to be 0*072%. The mean absorption half-life was 0*52h.
Table 2 summarizes the pharmacokinetic parameters of 
intravenous oxytocin in six male volunteers. The pharma­
cokinetic profile can be described by a two-compartment 
model. The distribution half-life (t£„) shows a relatively 
small variation among the volunteers (CV =  32-6%). The 
elimination half-life (t^) was 0*33 ±  0*23 h, (range 0*11- 
0-74 h, CV =  69*4%). The total body clearance (CL) was 
67-1 ±  l3*4Lh” 1 (range 47*7-83*0, CV =  20*0%) and the
Time (h)
F ig. 1. Oxytocin plasma concentration-time curves after adminis­
tration of an intravenous dose of lint, unit (1*71 /xg) oxytocin 
( - • - ,  ti -  0*28 h) and after sublingual administration of 400 int. 
units (684 fig) oxytocin (- - 0  - -, t! = 0*62 h) to subject 1.
steady state volume of distribution (Vdss) was 12*2 db 5*6 L 
(range 5-8-20*7 L, CV = 45*9%).
Table 3 summarizes the pharmacokinetic parameters of 
sublingual oxytocin in the same six volunteers. After sub­
lingual administration, the pharmacokinetic profile can be 
described by a one-compartment model. The bioavailability 
(F) is poor, subject-dependent and ranges between 0*007 and 
0-07% (CV =  50*0%) with the assumption that the total 
body clearance is similar after intravenous and sublingual 
administration. The lag time (tlag) was 0*20 ±  0-08 h (range 
0T2-0*30h, CV =  40%), the absorption half-life (t^bs) was 
0*45 ±  0*29 h, (range 0T2-0*80h, CV =  65*3%) and the 
apparent elimination half-life (t^) 0*69 ±  0-26 h, (range 
0*43-1-13, CV = 37*8%).
Two volunteers experienced flushes immediately after 
injection of lint, unit oxytocin (subjects 1 and 5). After 
sublingual administration no side-effects were noted.
Table 2. Pharmacokinetic parameters of intravenous oxytocin (1 int. unit).
Parameter Subjects Mean ±  s.d.
1 2 3 4 5 6
■Mi
Hi) 0*075 0*042 0*063 0*032 0*037 0-045 0*049 ±0*016
...(h) 0-3Î 0*39 0*74 0-11 0*13 0-28 0*33 ±  0*23
tvlRT (h) 0-26 0-15 0-25 0-99 0-12 0-21 0_33 ± 0-33
AUC(ngL-') 27-4 21-0 20-8 20'6 35-8 26*8
C L (L lr ')  62*5 63-3 82-1 83-0 47-7 63-7 « ' i  Í  i l ' f
Vd, (L) 28-2 35-5 87-0 13-6 8-78 25-8 33*2 ±28-1
Vd‘ (L) 16-2 9-17 207 8-24 5-80 13-3 12'2±5-6
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Table 3. Pharmacokinetic parameters of sublingual oxytocin (400 int. units).
Parameter Subjects Mean ±  s.d. P
1 2 3 4 5 6
F (%) 0*072 0*100 0112 0*106 0'0072 0*073 0*078 ±0*039 < 0*00001
t j a g  (h)
turn (h)
0*29 0-12 0*15 0*30 0*16 0*15 0*20 ±  0*08
0-59 1*08 1*03 1*34 0*48 0-77 0*88 ±  0*33
Cmax (ngmL-1) 7-86 4*12 3-89 3-09 6*32 4*41 4*95 ±1*78
t u  (h) 0-12 0*80 0*60 0-72 0*16 0*31 0*45 ±0*29
t£„ (h) 0-23 0*23¿ I f  > ^
U» (h) 0-43 0-56 0-62 0*73 2-91 M3 1*06 ±  0*94 0*091
2*91* 0*69 ±0*26**
MRT„ (h) 1-07 2*08 1*91 2*39 3-63 I'48 2*09 ±  0*88 0*0010
MAT (h) 0-52 1-82 1*51 1-10 3*34 M3 1*57 ±0*97
AUC(hngL-') 7-88 10-83 9*32 8*75 10*29 7*84 9*15 ±  1'24 <  0 - 0 0 0 1
CLS (Lh-') 62*5 62*6 82-1 83-0 34*9 63'7 64*8 ±  17*5 >0*8
Vd„ (L) 38*6 50-6 73-5 86-9 38-2 56-6 57*2 ±19*7 0*12
* Outlier, ** without outlier.
Discussion
Oxytocin is a posterior pituitary hormone which is not 
regulated by hypothalamic releasing hormones. It is synthe­
sized in the hypothalamus and then transported intracellu­
lar ly to the posterior pituitary, from which it is released into 
the circulation. Oxytocin has an important role in contrac­
tions during labour. The sensitivity of the uterus to oxytocin 
depends strongly on the amount of oxytocin-receptors, 
increasing with increasing gestational age. Honnebier
(1993) suggested that the demonstrated circadian rhythm 
of oxytocin at term plays a role in the onset of labour, 
influencing the shift from contractures to contractions. In 
therapeutic doses, oxytocin stimulates the contractions of 
uterine smooth muscle (Brazeau 1970). Its primary use is for 
induction of labour at term, when a large oxytocin receptor 
population is present in the uterus. It is also given intra­
muscularly postpartum to control uterine bleeding. Oxyto­
cin may be prepared by a process of extraction from the 
glands of oxen or other mammals or by synthesis. Oxytocin 
was isolated in 1928 from the posterior lobe of the pituitary 
gland and showed vasoactive, antidiuretic and uterotonic 
properties (Kamm et al 1928). In 1953, the synthesis of the 
polypeptide oxytocin was performed and it was marketed in 
1963 (Du Vigneaud et al 1953a, b).
According to the Pharmacological Basis of Therapeutics 
(Brazeau 1970; Rail 1990), and Martindale (Reynolds 1988) 
sublingual oxytocin is absorbed rapidly. Others have reported 
that sublingual absorption is unpredictable (Noriega-Guerra 
et al 1966). We conclude from our studies that oxytocin 
absorbtion by male volunteers (65% CV) after the lag time, 
cannot be reliably assessed. Sublingual absorption is pro­
longed and causes a long mean absorption half-life of 2 h and 
consequently a longer apparent tj and MRT. The mean 
pharmacokinetic lag time of 0*20 h in males corresponds to 
the latent periods of 13-96 min reported by Tobias (1975), 
and 31 min reported by Obolensky & Kupferschmied (1969) 
in non-pregnant women.
The total body clearance of 60 Lh“1 corresponds with the 
reported metabolic clearance rate (MCR) of IL m in" 1 
reported by Amico et al (1984, 1987), Dawood et al 
(1980), Leake et al (1980) and Thornton et al (1990).
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